| http://www.w3.org/ns/prov#value | - Wednesday, 29 June 2011AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC???s proprietary GEMS??? technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great un
|
